Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00079720" target="_blank" >RIV/00159816:_____/23:00079720 - isvavai.cz</a>

Výsledek na webu

<a href="https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202305769" target="_blank" >https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202305769</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/advs.202305769" target="_blank" >10.1002/advs.202305769</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles

Popis výsledku v původním jazyce

The application of lipid-based nanoparticles for COVID-19 vaccines and transthyretin-mediated amyloidosis treatment have highlighted their potential for translation to cancer therapy. However, their use in delivering drugs to solid tumors is limited by ineffective targeting, heterogeneous organ distribution, systemic inflammatory responses, and insufficient drug accumulation at the tumor. Instead, the use of lipid-based nanoparticles to remotely activate immune system responses is an emerging effective strategy. Despite this approach showing potential for treating hematological cancers, its application to treat solid tumors is hampered by the selection of eligible targets, tumor heterogeneity, and ineffective penetration of activated T cells within the tumor. Notwithstanding, the use of lipid-based nanoparticles for immunotherapy is projected to revolutionize cancer therapy, with the ultimate goal of rendering cancer a chronic disease. However, the translational success is likely to depend on the use of predictive tumor models in preclinical studies, simulating the complexity of the tumor microenvironment (e.g., the fibrotic extracellular matrix that impairs therapeutic outcomes) and stimulating tumor progression. This review compiles recent advances in the field of antitumor lipid-based nanoparticles and highlights emerging therapeutic approaches (e.g., mechanotherapy) to modulate tumor stiffness and improve T cell infiltration, and the use of organoids to better guide therapeutic outcomes. The implementation of advanced preclinical models such as tumor organoids, incorporating immune system cells and tumor extracellular matrix, will contribute to the development of innovative antitumor therapies such as mechanotherapy-assisted lipid-based immunotherapy.image

Název v anglickém jazyce

Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles

Popis výsledku anglicky

The application of lipid-based nanoparticles for COVID-19 vaccines and transthyretin-mediated amyloidosis treatment have highlighted their potential for translation to cancer therapy. However, their use in delivering drugs to solid tumors is limited by ineffective targeting, heterogeneous organ distribution, systemic inflammatory responses, and insufficient drug accumulation at the tumor. Instead, the use of lipid-based nanoparticles to remotely activate immune system responses is an emerging effective strategy. Despite this approach showing potential for treating hematological cancers, its application to treat solid tumors is hampered by the selection of eligible targets, tumor heterogeneity, and ineffective penetration of activated T cells within the tumor. Notwithstanding, the use of lipid-based nanoparticles for immunotherapy is projected to revolutionize cancer therapy, with the ultimate goal of rendering cancer a chronic disease. However, the translational success is likely to depend on the use of predictive tumor models in preclinical studies, simulating the complexity of the tumor microenvironment (e.g., the fibrotic extracellular matrix that impairs therapeutic outcomes) and stimulating tumor progression. This review compiles recent advances in the field of antitumor lipid-based nanoparticles and highlights emerging therapeutic approaches (e.g., mechanotherapy) to modulate tumor stiffness and improve T cell infiltration, and the use of organoids to better guide therapeutic outcomes. The implementation of advanced preclinical models such as tumor organoids, incorporating immune system cells and tumor extracellular matrix, will contribute to the development of innovative antitumor therapies such as mechanotherapy-assisted lipid-based immunotherapy.image

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NU23J-08-00035" target="_blank" >NU23J-08-00035: Integrace nových RNA-nanoterapeutik do organoidů rakoviny prsu odvozených od pacienta</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Advanced Science

ISSN

2198-3844

e-ISSN

2198-3844

Svazek periodika

11

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

21

Strana od-do

—

Kód UT WoS článku

001113841200001

EID výsledku v databázi Scopus

—